Novo Nordisk has officially launched the “Live Lighter” movement in the Philippines, a campaign that aims to change how Filipinos understand and manage obesity. Alongside the initiative, the healthcare company also introduced Wegovy®, a prescription treatment designed to help regulate appetite and support long-term weight management through science-based care.

The movement highlights that obesity is not simply about lifestyle choices or lack of discipline, but a chronic and complex disease influenced by biology, environment, and other health factors. According to Novo Nordisk Philippines General Manager Wei Sun, the goal of the campaign is to encourage a more compassionate and medically guided approach in addressing obesity in the country.

Wegovy®, which is based on semaglutide, works with the body’s natural processes to help control appetite, energy intake, and metabolism. Health experts shared that treatments like these could help individuals who struggle to maintain weight loss through traditional methods such as diet and exercise alone.

During the launch, Novo Nordisk also emphasized the growing impact of obesity in the Philippines, linking it to serious health conditions including type 2 diabetes, cardiovascular diseases, and certain cancers. Studies revealed that obesity continues to place a significant economic and healthcare burden on the country.

Through the Live Lighter movement, Novo Nordisk hopes to bring together healthcare professionals, patient advocates, media, and communities to promote awareness, reduce stigma, and improve access to evidence-based obesity care. The campaign ultimately aims to encourage Filipinos to see obesity as a treatable medical condition rather than a personal failure.

Continuing its commitment to transforming obesity care in the Philippines, Novo Nordisk Philippines has also partnered with Rose Pharmacy to expand access to patient-centered obesity management solutions in Cebu and across the Visayas.

The partnership aims to address ongoing challenges surrounding obesity care, including limited awareness, stigma, and access to proper treatment. Through Rose Pharmacy’s trusted network, more Filipinos will have easier access to reliable information, trained healthcare professionals, and science-based support throughout their health journey.

According to Wei Sun, General Manager of Novo Nordisk Philippines, obesity is a chronic and complex disease that requires long-term care and continuous support. By collaborating with Rose Pharmacy, the company hopes to help more Cebuanos and Visayan communities access proper treatment and sustainable healthcare solutions.

Rose Pharmacy General Manager Michael So also emphasized the important role pharmacies play in guiding patients toward better health. The partnership seeks to empower individuals living with obesity by providing accessible support and encouraging a more compassionate understanding of the condition.

The collaboration is part of Novo Nordisk’s broader “Live Lighter” movement, which promotes a science-based and patient-centered approach to obesity care in the country. Through partnerships like this, the company continues to advocate for better awareness, reduced stigma, and improved access to innovative treatments that can help Filipinos live healthier lives.